JW Pharmaceutical Corporation (KRX:001060)
South Korea
· Delayed Price · Currency is KRW 32,100
-400 (-1.23%)
Apr 29, 2026, 3:30 PM KST
JW Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 775,298 | 719,376 | 748,527 | 684,351 | 606,585 | Upgrade
|
| Other Revenue | -0 | -0 | -0 | - | - | Upgrade
|
| Revenue | 775,298 | 719,376 | 748,527 | 684,351 | 606,585 | Upgrade
|
| Revenue Growth (YoY) | 7.77% | -3.89% | 9.38% | 12.82% | 10.82% | Upgrade
|
| Cost of Revenue | 415,984 | 395,878 | 412,984 | 396,397 | 372,209 | Upgrade
|
| Gross Profit | 359,314 | 323,498 | 335,542 | 287,955 | 234,376 | Upgrade
|
| Selling, General & Admin | 222,622 | 210,610 | 204,728 | 182,652 | 171,220 | Upgrade
|
| Research & Development | 45,447 | 36,237 | 33,671 | 33,736 | 19,884 | Upgrade
|
| Operating Expenses | 271,437 | 240,766 | 238,911 | 227,464 | 203,528 | Upgrade
|
| Operating Income | 87,877 | 82,733 | 96,631 | 60,490 | 30,848 | Upgrade
|
| Interest Expense | -4,424 | -10,033 | -12,562 | -9,387 | -7,337 | Upgrade
|
| Interest & Investment Income | 3,338 | 4,962 | 6,322 | 5,814 | 1,981 | Upgrade
|
| Earnings From Equity Investments | 2,259 | 1,387 | 621.06 | -955.41 | -1,149 | Upgrade
|
| Currency Exchange Gain (Loss) | -618.56 | 1,087 | -1,817 | -2,300 | -925.96 | Upgrade
|
| Other Non Operating Income (Expenses) | -1,126 | 2,253 | -36,102 | 5,425 | -1,191 | Upgrade
|
| EBT Excluding Unusual Items | 87,305 | 82,390 | 53,095 | 59,088 | 22,227 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1,578 | 790.9 | 2,830 | -8,908 | -646.8 | Upgrade
|
| Gain (Loss) on Sale of Assets | -46.76 | 464.91 | -1,088 | 3.28 | -1,048 | Upgrade
|
| Asset Writedown | - | -1,476 | - | -4,821 | - | Upgrade
|
| Other Unusual Items | - | 249.74 | - | - | - | Upgrade
|
| Pretax Income | 88,836 | 82,420 | 54,836 | 45,362 | 20,533 | Upgrade
|
| Income Tax Expense | 27,325 | 17,379 | 16,406 | 15,509 | 21,974 | Upgrade
|
| Earnings From Continuing Operations | 61,511 | 65,040 | 38,430 | 29,853 | -1,441 | Upgrade
|
| Minority Interest in Earnings | - | - | -1,424 | 2,039 | 473.6 | Upgrade
|
| Net Income | 61,511 | 65,040 | 37,006 | 31,892 | -967.85 | Upgrade
|
| Net Income to Common | 61,511 | 65,040 | 37,006 | 31,892 | -967.85 | Upgrade
|
| Net Income Growth | -5.43% | 75.75% | 16.04% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 24 | 25 | 24 | 23 | 23 | Upgrade
|
| Shares Outstanding (Diluted) | 24 | 25 | 24 | 23 | 23 | Upgrade
|
| Shares Change (YoY) | -1.32% | 3.34% | 2.49% | 0.07% | -0.05% | Upgrade
|
| EPS (Basic) | 2534.00 | 2644.00 | 1554.67 | 1373.14 | -41.70 | Upgrade
|
| EPS (Diluted) | 2534.00 | 2644.00 | 1554.67 | 1373.14 | -41.70 | Upgrade
|
| EPS Growth | -4.16% | 70.07% | 13.22% | - | - | Upgrade
|
| Free Cash Flow | 84,625 | 71,079 | 59,871 | 46,845 | 10,657 | Upgrade
|
| Free Cash Flow Per Share | 3486.17 | 2889.49 | 2515.25 | 2016.97 | 459.20 | Upgrade
|
| Gross Margin | 46.34% | 44.97% | 44.83% | 42.08% | 38.64% | Upgrade
|
| Operating Margin | 11.34% | 11.50% | 12.91% | 8.84% | 5.08% | Upgrade
|
| Profit Margin | 7.93% | 9.04% | 4.94% | 4.66% | -0.16% | Upgrade
|
| Free Cash Flow Margin | 10.91% | 9.88% | 8.00% | 6.84% | 1.76% | Upgrade
|
| EBITDA | 106,624 | 101,834 | 119,206 | 77,327 | 46,960 | Upgrade
|
| EBITDA Margin | 13.75% | 14.16% | 15.93% | 11.30% | 7.74% | Upgrade
|
| D&A For EBITDA | 18,748 | 19,101 | 22,575 | 16,836 | 16,112 | Upgrade
|
| EBIT | 87,877 | 82,733 | 96,631 | 60,490 | 30,848 | Upgrade
|
| EBIT Margin | 11.34% | 11.50% | 12.91% | 8.84% | 5.08% | Upgrade
|
| Effective Tax Rate | 30.76% | 21.09% | 29.92% | 34.19% | 107.02% | Upgrade
|
| Advertising Expenses | 22,691 | 24,252 | 22,690 | 22,673 | 18,416 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.